Company news
MYND Life Sciences Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Management Cease Trade Order Status Report
April 9, 2025
Management Cease Trade Order Granted
March 3, 2025
MYND Life Sciences Announces Shares for Debt Transaction
February 11, 2025
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
January 17, 2025
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
January 10, 2025
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
November 22, 2024
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
November 12, 2024
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
January 30, 2024
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
December 5, 2023
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
December 4, 2023
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
October 25, 2023
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
September 11, 2023
MYND Life Sciences Inc. Has Management CTO Revoked
May 9, 2023
MYND Life Sciences Inc. Provides Default Status Report
April 25, 2023
MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report
March 28, 2023
MYND Life Sciences Inc. Achieves a Major Milestone and Provides Default Status Report
March 14, 2023
MYND Life Sciences Inc. Granted Management Cease Trade Order
March 1, 2023
MYND Life Sciences Announces the Sale of Leasehold Tenant Improvements and Health Canada Cannabis License
February 9, 2023
MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
November 30, 2021
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
November 18, 2021
MYND Life Sciences Inc: . Announces RSU Grant
September 29, 2021
MYND Life Sciences: Life Sciences Announces $3 Million Convertible Debenture Unit Offering
August 26, 2021
MYND Life Sciences: Life Sciences Announces DTC Eligibility
August 11, 2021
MYND Life Sciences: Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs
June 10, 2021
MYND Life Sciences: Life Sciences announces Depression Biomarker Diagnostic Program
June 1, 2021
MYND Life Sciences Inc: . Establishes Scientific Advisory Board
May 31, 2021
MYND Life Sciences Inc: . Announces Public Listing on the Canadian Securities Exchange
May 27, 2021
Decks
- Investor Presentation (January 2021)
Investor deck · 21 slides · January 2021